Molecular Partners narrows focus to radiotherapy, plans workforce cuts
The company said emerging MP0712 data support a pivot to radiopharmaceuticals, with job cuts and a cash runway into late 2027.
SEC filing
1 story
The company said emerging MP0712 data support a pivot to radiopharmaceuticals, with job cuts and a cash runway into late 2027.
SEC filing